Literature DB >> 19503016

Middle ear exploration in patients with Ménière's disease who have failed outpatient intratympanic gentamicin therapy.

Benjamin T Crane1, Lloyd B Minor, Charles C Della Santina, John P Carey.   

Abstract

OBJECTIVE: Treatment of medically refractory Ménière's disease (MD) with intratympanic (IT) gentamicin has now become a standard therapy. This procedure is effective in controlling vertigo attacks, but approximately 10% of patients do not have an adequate response. The objective of the current study was to evaluate the option of middle ear exploration with direct application of gentamicin to the round window (MEE-G) in patients with persistent MD after transtympanic injection of gentamicin. STUDY
DESIGN: A retrospective chart review of 191 patients with MD treated with IT gentamicin revealed 16 who failed to have symptomatic relief after transtympanic injection. Options discussed with these patients included labyrinthectomy, vestibular nerve section, and MEE-G.
SETTING: Tertiary referral center. PATIENTS: Eight patients opted for MEE-G. INTERVENTION: Patients were taken to the operating room for MEE-G. After removal of the round window obstruction, gentamicin-soaked pledgets were placed for at least 30 minutes. MAIN OUTCOME MEASURES: Control of MD-related vertigo and need for additional therapy.
RESULTS: At the time of MEE-G, all 8 patients were found to have adhesions, bone dust blocking the round window, or a thickened round window membrane. In 6 of these patients, vertigo symptoms due to MD either resolved with no further therapy (4 patients) or with subsequent IT gentamicin injections in clinic (2 patients). The remaining 2 patients underwent a vestibular nerve section, which resolved MD symptoms in each case.
CONCLUSION: Anatomic barriers to the round window membrane may be a significant cause of IT gentamicin failure, and MEE-G can be considered before ablative therapy in this subset of patients with Ménière's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19503016     DOI: 10.1097/MAO.0b013e3181a66d2b

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  9 in total

1.  Does intratympanic gadolinium injection predict efficacy of gentamicin partial chemolabyrinthectomy in Menière's disease patients?

Authors:  Gerd Claes; Luc Van den Hauwe; Floris Wuyts; Paul Van de Heyning
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-28       Impact factor: 2.503

2.  Controlled release dexamethasone implants in the round window niche for salvage treatment of idiopathic sudden sensorineural hearing loss.

Authors:  Stefan K Plontke; Alexander Glien; Torsten Rahne; Karsten Mäder; Alec N Salt
Journal:  Otol Neurotol       Date:  2014-08       Impact factor: 2.311

3.  Treatment of Menière's Disease.

Authors:  Jeffrey D Sharon; Carolina Trevino; Michael C Schubert; John P Carey
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 4.  Is gentamycin delivery via sustained-release vehicles a safe and effective treatment for refractory Meniere's disease? A critical analysis of published interventional studies.

Authors:  Petros V Vlastarakos; Emily Iacovou; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-13       Impact factor: 2.503

5.  Fully Endoscopic Retrosigmoid Vestibular Nerve Section for Refractory Meniere Disease.

Authors:  Pradeep Setty; Seilesh Babu; Michael J LaRouere; Daniel R Pieper
Journal:  J Neurol Surg B Skull Base       Date:  2016-02-13

6.  Dynamics in Endolymphatic Hydrops & Symptoms in Meniere's Disease After Endolymphatic Duct Blockage, Preliminary Results.

Authors:  Jun He; Anquan Peng; Junjiao Hu; Zhiwen Zhang; Yichao Chen; Qin Wang; Wei Liu; Huang Chao; Kai Deng; Wenqi Jiang
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

7.  Safety and audiological outcome in a case series of tertiary therapy of sudden hearing loss with a biodegradable drug delivery implant for controlled release of dexamethasone to the inner ear.

Authors:  Stefan K Plontke; Arne Liebau; Eric Lehner; Daniel Bethmann; Karsten Mäder; Torsten Rahne
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

8.  Partial Aminoglycoside Lesions in Vestibular Epithelia Reveal Broad Sensory Dysfunction Associated with Modest Hair Cell Loss and Afferent Calyx Retraction.

Authors:  David R Sultemeier; Larry F Hoffman
Journal:  Front Cell Neurosci       Date:  2017-10-27       Impact factor: 5.505

9.  Modulation of hearing function following the downgrading or upgrading of endolymphatic hydrops in Meniere's disease patients with endolymphatic duct blockage.

Authors:  Anquan Peng; Junjiao Hu; Qin Wang; Wenqi Jiang; Wei Liu; Zhiwen Zhang; Chao Huang; Yichao Chen
Journal:  PLoS One       Date:  2020-10-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.